23andMe raises $79M as it ramps up R&D work

Richard Scheller

23andMe has filed documents with the SEC stating that it has raised $79 million of a $150 million round. The fundraising comes soon after the company revealed plans to dive into the drug development world, recruiting Genentech's Richard Scheller as its chief scientific officer. 23andMe plans to search the genetic info it's gathered on 850,000 people for clues to new therapeutics. And it's also been doing R&D-related deals with the likes of Pfizer as well as Genentech. SEC

Suggested Articles

The FDA slapped a partial clinical hold on the phase 2/3 study of Inovio’s COVID-19 vaccine because it has “additional questions” about the trial.

Preclinical inflammatory disease biotech Ilias Biologics has grabbed a $20.6 million funding round as it eyes a 2021 human test of its leading asset.

Aligos Therapeutics is shooting for a $100 million IPO to help drive its early work on a functional cure for chronic hepatitis B as well as COVID-19.